Context: Few studies have assessed factors associated with severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) in adults with type 1 diabetes (T1D).
S
evere hypoglycemia (SH) and diabetic ketoacidosis (DKA) are major acute complications of type 1 diabetes (T1D). Many studies are available concerning the prevalence of these complications in children and adolescents with T1D, but there is a paucity of data in adults. Although recent data are available from European registries (1, 2), recent U.S. data are largely from clinical trials, which may not be representative (3, 4) . To provide current data in clinical practice settings in the United States, we used the large database of the T1D Exchange clinic registry to assess the frequencies of and identify factors associated with SH and DKA in adults with T1D. We hypothesized that rates of DKA would be positively associated with hemoglobin A1c (HbA1c) and that SH would be inversely associated with HbA1c. Moreover, we hypothesized that rates of DKA and SH would be associated with factors such as socioeconomic status, age, pump use, and diabetes duration.
Subjects and Methods
The T1D Exchange Clinic Network includes 70 U.S.-based pediatric and adult endocrinology practices. A registry of individuals with T1D commenced enrollment in September 2010 (5) . Each clinic received approval from an institutional review board, and informed consent was obtained according to institutional review board requirements. Data were collected for the registry's central database from the participant's medical record and by having the participant complete a comprehensive questionnaire, as previously described (5) . This report includes data on 7012 participants enrolled at 44 of the sites through August 1, 2012 , who were at least 26 years old and had duration of T1D of at least 2 years.
Information on the occurrence of SH and DKA in the previous 12 months was obtained from the participant. Initially, SH was defined as an episode in which the assistance of another individual was needed or glucagon was given. However, it became apparent that the interpretation of 'needing assistance' varied, and in some cases, glucagon was being given for mild hypoglycemia to avoid SH. As a result, the questionnaire was modified to change the participant-reported SH definition to be an episode in which hypoglycemia resulted in seizure or loss of consciousness (LOC); glucose data confirming an event were not collected. Participant-reported DKA was defined as the occurrence of ketoacidosis that resulted in overnight hospitalization. SH data were analyzed for the 4973 participants (71%) who completed the modified questionnaire with the seizure/LOC definition, whereas DKA data were available for 6796 participants (97%). In addition to participant reporting, information on the occurrence of DKA and SH also was collected from the clinics' medical records. Clinic-documented DKA was defined as having hyperglycemia and meeting all of the following criteria: 1) symptoms such as polyuria, polydipsia, nausea, or vomiting; 2) serum ketones or large/moderate urine ketones; 3) arterial blood pH Ͻ7.30, or venous pH Ͻ7.30, or serum bicarbonate Ͻ15 mmol/L; and 4) treatment provided in a healthcare facility.
Primary analyses used the participant-reported events because the data obtained from medical records were considered to be frequently incomplete. Additional analyses were performed using the clinic-reported cases.
Statistical methods
The occurrence of at least 1 event was considered to be more reliable than the number of events reported by a participant when multiple events in the past 12 months were reported. Therefore, frequencies of SH and DKA were reported as the occurrence of 1 or more events in the previous 12 months. Separate logistic regression models evaluated the association of baseline demographic and clinical factors with the occurrence of a participantreported SH or DKA event in the previous 12 months. Factors with a P value Ͻ .10 from individual factor models were included in an initial multivariate model, and then a backward elimination procedure was used to remove variables with a P value Ͼ .01. A forward selection process resulted in a similar model. Tests of significance were reported from models using continuous or ordinal variables and odds ratios were reported from models using the categorical variables.
Data analyses used SAS software, version 9.3 (2011; SAS Institute Inc, Cary, North Carolina). All P values are 2-sided. In view of the multiple comparisons and large sample size, only P values Ͻ .01 were considered significant.
Results
The cohort included 7012 participants 26 to 93 years old; 54% were female, and 91% were non-Hispanic white. Mean HbA1c (ϮSD) was 7.7% (61 mmol/mol) Ϯ 1.2% (13.1 mmol/mol). Median diabetes duration was 24 years (interquartile range 15 to 34 years). Characteristics were similar in the cohort with available DKA data (n ϭ 6797) and those with available SH data (n ϭ 4973) (Supplemental Table 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org).
Severe hypoglycemia
One or more SH events (seizure or LOC) within 12 months was reported by 11.8% of the 4973 participants with available data. SH frequency increased with longer diabetes duration, with the 12-month frequency of 1 or more events being 18.6% in the 758 participants with diabetes for Ն40 years ( Figure 1A and Table 1 ). Although the frequency of SH increased with older age (P Ͻ .001), as can be seen in Figure 1A , the age effect was largely explained by diabetes duration, and in the multivariate model, age was not a significant factor (Table 1) . With respect to HbA1c levels, SH frequency was lowest with HbA1c levels 7.0% (53 mmol/mol) to 7.5% (58 mmol/ mol), with frequency being higher at levels above or below this range ( Figure 2A and Table 1 ). No evidence of a difference in SH frequency was found between adults with HbA1c levels of 8.0% to 9.0%, 9.0% to 10.0%, and Ͼ10.0% (P Ͼ .05). There was a trend (P ϭ .01) for individuals with low (Ͻ0.43 U/kg) insulin requirements to have a higher SH frequency independent of body mass index (BMI) (which was not associated with SH frequency).
In addition to diabetes duration and glycemic control, SH was more likely to occur in participants who had lower education levels (P ϭ .003), had lower household income (P Ͻ .001), and did not have private insurance (P Ͻ .001 in multivariate model). In univariate models, non-Hispanic black and Hispanic participants had a higher frequency of SH compared with non-Hispanic whites, injection users had a higher frequency of SH than pump users, and current smokers had a higher frequency of SH than nonsmokers, but none of these factors were significant (P Ͻ .01) in the multivariate model.
Diabetic ketoacidosis
One or more DKA events within 12 months were reported by 4.8% of the 6796 participants. Frequency of DKA was lower with increasing age. However, the age effect was largely explained by HbA1c level, which was strongly associated with the occurrence of a DKA event, ranging from 1.6% in the 864 participants with HbA1c level Ͻ6.5% (Ͻ48 mmol/mol) to 21.0% in the 334 participants with HbA1c Ն10.0% (Ն86 mmol/mol) ( Figure  2B and Table 2 ). Unlike with SH, frequency of DKA was not associated with diabetes duration ( Figure 1B ). In addition to HbA1c level, a higher frequency of DKA was associated with lower socioeconomic status based on education level, income, and insurance status (P Ͻ .001 for each in multivariate model) and female gender (P ϭ .008). In univariate models, non-Hispanic black and Hispanic participants had higher frequencies of DKA than non-Hispanic whites, and current smokers had higher frequency of DKA than nonsmokers, but after adjusting for socioeconomic status, neither factor was significant in the multivariate model. Frequency of DKA was not significantly different between pump and injection users.
Participant-reported versus clinic-reported events
The frequency of at least 1 DKA or SH event in the past 12 months was lower from clinic-reported data from medical record review compared with participant-reported data (3.6% versus 11.8% for SH and 3.2% versus 4.8% for DKA). Logistic models using clinic-reported SH and DKA events to assess associated factors produced results similar to the models using participant-reported events (Supplemental Tables  2 and 3 ).
Discussion
Using the T1D Exchange clinic registry data, we determined the frequencies of SH and DKA over the past 12 months in adults with T1D who were being treated at endocrinology practices in the United States. Compared with the pediatric and young adult cohort in the T1D Exchange clinic registry, the 12-month frequency of hypoglycemia-induced seizure/LOC in adults was higher (11.8% versus 6.1%) and DKA frequency was lower (4.8% versus 9.6%) (5). Higher frequencies of both SH and DKA were associated with lower socioeconomic status, consistent with previous reports (6 -10).
Our 12-month frequency of at least 1 SH episode with seizure/LOC (11.8%) is substantially higher than the 2.2% 6-month frequency reported for control group participants with comparable characteristics in the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF CGM) randomized clinical trial (4) and the 4.8% 12-month frequency in the Sensor-Augmented Pump Therapy for A1c Reduction (STAR3) trial (3) (R. Bergenstal, MD, personal communication, November 2012). This suggests that clinical trial data may not be an appropriate source for estimating the real-world frequency of SH. Most other registry and observational studies have reported SH frequency based on a definition of an event in which the assistance of another person was needed. If it is assumed that about one-third of SH events using this definition involved seizure/LOC, then the data on the 12-month SH frequency are similar to our SH frequency: 31.5% in the Eurodiab Prospective Complications Study (2), 36.7% in a Danish-English survey (7), 40.5% in a Dutch study (11) , and 27% in a Swedish survey Based on the work of Cryer (14) and others, it is likely that the increased risk with longer duration is related to the loss of endogenous insulin secretion (C-peptide negative) removing any autoregulatory capability to reduce excessive insulin, a greater prevalence of defective glucose counterregulation with hypoglycemic unawareness including a reduced plasma glucagon response to hypoglycemia, and loss of the epinephrine response to hypoglycemia (hypoglycemia-associated autonomic failure). Impairments related to chronic diabetes-related complications and other comorbidities also could be contributing factors. We did not find an association between SH and gender in contrast with the JDRF CGM randomized trial and the Diabetes Control and Complications Trial (DCCT), which found a higher SH rate in females (15) .
The lowest SH frequency was seen in those with HbA1c levels in the range of 7.0% (53 mmol/mol) to 7.5% (58 mmol/mol), with the frequency being higher in those with HbA1c levels Ͻ7.0% (Ͻ53 mmol/mol) or Ͼ7.5% (Ͼ58 mmol/mol). These data support the contention that hypoglycemia is an important barrier for the achievement of near-normal glycemic control in T1D. There was a suggestion in the data that SH frequency might be higher in those who are the most insulin sensitive (based upon lower insulin requirements), but there was not an association between SH and BMI. This suggests that the ability to achieve glycemic targets varies in people with T1D. This may be related to differences in C-peptide status, insulin sensitivity (independent of obesity), and/or varying capacities to secrete glucagon and other factors. These data suggest that the avoidance of SH requires setting individualized flexible glycemic targets, with caution in recommending a goal HbA1c of Ͻ7.0% (Ͻ53 mmol/mol), especially in older patients with longstanding diabetes who experience frequent SH. On the other end of the spec- trum, the high rates of SH in poorly controlled patients demonstrate that elevated HbA1c levels, per se, do not protect against SH. We did not find an association of smoking and SH in contrast to the findings of other studies (8, 16) . With respect to DKA, the frequency not surprisingly was highest in those with higher HbA1c levels, occurring within the previous year in 21.0% with HbA1c Ն10.0% (Ն86 mmol/mol). Notably, the frequency was no higher in pump users than injection users, an important finding because DKA is a potential risk with pump infusion site failure. As with SH, DKA rates in clinical trials are likely not good estimates of real-world rates. In the JDRF CGM trial and Sensor-Augmented Pump Therapy for A1c Reduction (STAR3) trial, DKA occurred in none of the adults (3, 4) . Current DKA data in adults from registries and observational studies are limited. The Eurodiab study reported an annual frequency of 8.6% from 1989 to 1991 (17) .
In evaluating the data generated from this large registry, it is important to recognize that the cohort is not population-based and participation in the cohort is predicated on being followed by an endocrinologist at a participating center. This could affect the representativeness of the cohort, particularly because many adults with T1D may not be regularly cared for by an endocrinologist. As a result, estimated frequencies of SH and DKA could be biased, although we cannot surmise whether the frequencies would be more likely to be over-or underestimates. Nevertheless, the T1D Exchange data likely are the best currently available data on the frequency of SH and DKA in the United States. A lack of representativeness, even if present, is not likely to affect the interpretation of the analyses of factors associated with SH or DKA.
A registry such as the T1D Exchange provides meaningful real-world data that may better represent what occurs to patients than does data collected in controlled clinical trials. The tradeoff is that the data cannot be as readily confirmed as would be the case in a prospective trial with frequent patient contact and prospective recording of events. We found differences in the SH and DKA event data collected directly from the patient participant and from data extraction from the medical record. We believe that the discrepancies between the 2 more likely reflect underreporting in the medical records than overreporting by the participants. It is likely that not all events are recorded in the medical record particularly for SH, which may not require the involvement of the diabetes management team. In some respects, the use of electronic health records has made data extraction of SH and DKA events from existing data more problematic rather than less, in that insufficient information may have been recorded to fully classify the severity of the events, assuming that the events were even captured. Although the frequencies of SH and DKA events differed between self-report and medical record review, it is notable that the results with respect to associated factors were similar using either data source.
In comparing our results with those of other studies, it is important to distinguish between SH requiring assistance and SH resulting in seizure or LOC. Initially in the registry, we queried the participants about SH events that required the assistance of another individual due to an impaired cognitive state or the administration of glucagon. After initial testing with the questionnaire, we con- cluded that the interpretation of what constituted an SH event varied and that glucagon was sometimes given for mild hypoglycemia. Although it is possible that other conditions could cause seizures and LOC, we changed the data collection form to record only events resulting in seizure or LOC, believing that such events would more dependably reflect SH and be more reliably reported by the participant or parent.
Our DKA results largely parallel previous studies, providing similar insights. With respect to SH, 2 findings have important implications for patient management: the strong association of SH with longstanding diabetes and the lower SH frequency in those with HbA1c levels near goal (7.0% [53 mmol/mol] to 7.5% [58 mmol/mol]) compared with those who achieve the goal of Ͻ7.0% (Ͻ53 mmol/mol) or have higher HbA1c levels. Not only will SH not be abolished with current diabetes therapies, but it will also remain an obstacle to optimizing glycemic control. To reduce SH in adults with longstanding diabetes, given the limitation of current therapies, consideration should be given to modifying HbA1c goals, particularly in patients with very low HbA1c levels and SH. In addition to hypoglycemic risk, the decision to raise the target HbA1c should take into consideration age, self-care capacities, presence of comorbidities including vascular complications, and life expectancy.
